Abstract: Cell and gene therapy supply chains are uniquely complex, requiring precise coordination, regulatory compliance, and robust logistics to ensure timely delivery of life-saving treatments.

Abstract: Choosing between modular and fully integrated manufacturing platforms is a critical decision for cell therapy developers, impacting scalability, cost efficiency, and commercial viability.

Abstract: Process characterization is essential for cell therapy programs, ensuring consistent, safe, and effective products that meet regulatory standards.

Abstract: Cell therapies have complex manufacturing needs since the final drug product is viable cells comprising thousands of proteins, lipids and carbohydrates that can change with every manipulation step.

Abstract: Open steps in cell therapy manufacturing expose products to contamination risk, operational complexity, and scalability limitations.

Abstract: Cell therapy manufacturing demands rigorous quality control, as living cell products cannot be terminally sterilized and are often produced in small batches.

Abstract: Cell therapy manufacturing is advancing rapidly, offering new therapeutic options for challenging diseases, but the complexity of production makes raw material selection a critical determinant of success.

Abstract: As cell therapies advance toward commercialization, the industry is increasingly prioritizing manufacturing optimization and capacity.

Abstract: CAR-T therapies have proven their curative potential, but cell therapy developers continue to face challenges related to manufacturing complexities, costs, scalability, regulatory compliance, and supply chain management.

Summary: Catalent’s advanced iPSC-based platforms offer GMP-ready solutions for gene editing and cell differentiation, enabling partners to streamline therapeutic development.